Industry calls Union Budget 2021-22 ambitious but awaits implementation
Industry calls Union Budget 2021-22 ambitious but awaits implementation
01 February 2021 | News
Image Credit: shutterstock.com
Soon after the Union Budget 2021-22 was presented by the Finance Minister Nirmala Sitharaman where she strongly positioned Health & Wellbeing as one of the 6 crucial pillars of Aatma Nirbhar Bharat, industry s responses started pouring in.
BioSpectrum brings to you the post-budget reactions of the pharma & healthcare industry-
I am happy to see the investment in healthcare increase to such a level because it has been long overdue.
Kiran Mazumdar Shaw, Executive Chairperson, Biocon, Bengaluru
Setting up of rural and urban health and wellness centres could be an opportunity to create a PPP model. The partnership-driven approach is a sure step for the entities to bring to these hospitals their inherent areas of strength, thus building a quality model of care. Thi
The Elecsys Anti-SARS-CoV-2 S targets antibodies, which are directed against the particular region of the viral spike protein responsible for binding to the host cell receptor, which is required for the virus to enter the host cell
Roche Diagnostics launches Elecsys Anti-SARS-CoV-2Â S test in India
Roche Diagnostics launches Elecsys Anti-SARS-CoV-2Â S test in India
22 January 2021 | News The Elecsys Anti-SARS-CoV-2Â S targets antibodies which are directed against the particular region of the viral spike protein
Source: diagnostics.roche.com
Roche Diagnostics India has announced the launch of its antibody test SARS-CoV-2 test-Elecsys Anti-SARS-CoV-2 S. The test is CE IVD approved and has received ICMR and CDSCO approval in India. It is an in vitro test, that quantifies antibodies against the receptor-binding domain (RBD) of spike (S) protein SARS-CoV-2 in human serum and plasma, and determines the body’s immune response to the virus.